BPC-157 + TB-500 (20 mg Blend) Dosage Protocol

Plan based on a 4–8 week daily protocol (standard approach at ~1 mg/day maintenance).

• Peptide Vials (BPC-157 + TB-500 20 mg Blend):
  • 4 weeks (28 doses at ~0.67–1.0 mg/day): 2 vials
  • 6 weeks (42 doses): 3 vials
  • 8 weeks (56 doses): 3–4 vials
• Insulin Syringes (U-100):
  • Per week: 7 syringes (1/day)
  • 4 weeks: 28 syringes
  • 6 weeks: 42 syringes
  • 8 weeks: 56 syringes
• Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
  • 4 weeks (2 vials): 6 mL → 1 × 10 mL bottle
  • 6 weeks (3 vials): 9 mL → 1 × 10 mL bottle
  • 8 weeks (4 vials): 12 mL → 2 × 10 mL bottles
• Alcohol Swabs: One for the vial stopper + one for the injection site each day.
  • Per week: 14 swabs (2/day)
  • 4 weeks: 56 swabs → recommend 1 × 100-count box
  • 6 weeks: 84 swabs → recommend 1 × 100-count box
  • 8 weeks: 112 swabs → recommend 2 × 100-count boxes

BPC-157 + TB-500 20 mg

View Supplier

U-100 syringes

View Supplier

Bacteriostatic water

View Supplier

Alcohol swabs

View Supplier

Practice preparing this vial with the verified strength and final volume from this protocol.

• Reconstitute: Add 3.0 mL bacteriostatic water → ~6.67 mg/mL total concentration (~3.33 mg/mL of each peptide).
• Typical daily range: 250–500 mcg BPC-157 + 250–500 mcg TB-500 (500–1,000 mcg total blend) once daily.
• Easy measuring: At 6.67 mg/mL total, 1 unit = 0.01 mL ≈ 66.7 mcg total (~33.3 mcg of each peptide) on a U-100 insulin syringe.
• Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); follow product-specific use-by instructions.

BPC-157 (Body Protection Compound-157) is a 15-amino-acid peptide fragment derived from human gastric juice, studied for its cytoprotective and tissue-repair properties across gastrointestinal, musculoskeletal, and neurological systems^[1][2]. TB-500 (Thymosin β4) is a 43-amino-acid peptide involved in cell migration, angiogenesis, and wound healing^[3][4]. This blend combines both peptides for synergistic tissue-repair research applications.

This 20 mg blend contains 10 mg of BPC-157 and 10 mg of the material labeled TB-500. The vial strength changes concentration, per-component yield, and U-100 syringe conversion. It does not establish a clinical dose or make evidence for either ingredient interchangeable with evidence for the combined product.

• Strength-specific calculation: A 3.0 mL final volume produces approximately 6.67 mg/mL total blend, or approximately 3.33 mg/mL of each component.
• Evidence status: A 2025 systematic review found that the BPC-157 musculoskeletal literature was overwhelmingly preclinical, while human evidence was limited and did not evaluate this combination.^[1]
• TB-500 distinction: Human thymosin beta-4 studies investigated full-length synthetic or recombinant thymosin beta-4 under controlled protocols. Those results do not validate an injectable TB-500 fragment schedule or a BPC-157 + TB-500 blend.^[9][10]
• Existing chart: The dosage table above retains this page’s established educational calculation schedule. It is not presented as an FDA-approved regimen, a consensus standard, or a schedule derived from a combined human trial.

The page converts peptide mass into liquid volume. A 20 mg vial reconstituted to 3.0 mL contains about 6.67 mg of total blend per mL. Because the blend is labeled as equal parts BPC-157 and TB-500, each mL contains approximately 3.33 mg of each component.

Total blend amount ÷ 6.67 mg/mL = liquid volume; liquid volume × 100 = U-100 units.

• 7.5 units equals 0.075 mL and approximately 500 mcg total blend, or about 250 mcg of each component.
• 10 units equals 0.10 mL and approximately 667 mcg total blend, or about 333 mcg of each component.
• 15 units equals 0.15 mL and approximately 1 mg total blend, or about 500 mcg of each component.

U-100 units are volume markings, not peptide international units. The same syringe marking represents a different peptide mass when the vial strength or final volume changes. A peptide dosage calculator can reproduce this arithmetic, but it cannot select a dose or establish that the displayed schedule is safe or effective.

BPC-157 is a 15-amino-acid peptide investigated in laboratory and animal models. Rat studies reported changes in Achilles tendon healing, functional recovery, vascular response, and ligament repair after experimentally produced injuries.^[2][3][4] These findings are hypothesis-generating and do not establish a BPC-157 dosage for people.

Human research remains limited. A small pilot report in 12 women evaluated a single, procedure-specific intravesical BPC-157 administration for interstitial cystitis; it was not a subcutaneous musculoskeletal protocol and did not study TB-500 or a combined 20 mg vial.^[5] The recent orthopedic systematic review identified 35 preclinical studies and only one clinical study in its included evidence base, emphasizing the translational gap between animal findings and routine human use.^[1]

Thymosin beta-4 is a naturally occurring 43-amino-acid peptide associated with actin binding, cell migration, angiogenesis, and tissue-repair signaling in experimental research.^[7][8] TB-500 is commonly described as a thymosin beta-4-related fragment or derivative, but a product label does not prove that a research vial is chemically or clinically interchangeable with the full-length molecule used in published trials.

Controlled human studies administered full-length synthetic or recombinant thymosin beta-4 intravenously to healthy volunteers and assessed safety, tolerability, pharmacokinetics, and antibodies.^[9][10] A separate phase 2 study evaluated topical thymosin beta-4 for venous ulcers.^[11] None of those studies tested the subcutaneous TB-500 fragment together with BPC-157, and none validates the site’s vial-based calculation schedule.

The two ingredients are discussed together online because both are associated with tissue-repair research. That shared theme is not the same as evidence for a fixed-ratio blend. No cited controlled human trial establishes the efficacy, safety, route, duration, or dose of a 10 mg + 10 mg BPC-157 and TB-500 combination.

• BPC-157 evidence: predominantly animal, in-vitro, review, and limited observational or pilot human data.^[1][16]
• Thymosin beta-4 evidence: includes controlled studies of full-length material, but those formulations and routes are not substitutes for TB-500 fragment evidence.^[9][10]
• Blend evidence: the arithmetic is verifiable from vial mass and final volume, but the combined schedule remains an educational calculation framework rather than a validated treatment protocol.

For that reason, the chart keeps per-peptide amounts visible and avoids using academic citations to imply that its community-reported schedule was tested in the cited studies.

Preclinical BPC-157 research has examined nitric-oxide signaling, VEGF-related angiogenesis, fibroblast activity, collagen organization, and tendon or ligament recovery.^{[2][3][4][16]} Thymosin beta-4 research has examined actin sequestration, cell migration, inflammation, angiogenesis, and repair signaling.^[7][8]

Mechanistic overlap can support a research hypothesis, but it does not prove synergy. A proposed combined mechanism must be tested in an appropriate formulation, dose range, route, model, and population before claims about additive or superior outcomes are justified.

Several details prevent direct translation of the available literature into a BPC-157 + TB-500 20 mg dosage recommendation:

• Molecule: full-length thymosin beta-4 is not automatically equivalent to a shorter TB-500 fragment.
• Route: intravenous, topical, intravesical, oral, intraperitoneal, and subcutaneous protocols can have different exposure and safety profiles.
• Population: healthy-volunteer safety data and disease-specific pilot studies cannot establish outcomes for injury recovery in a general population.
• Formulation: trial material, excipients, sterility controls, and manufacturing specifications may differ from a lyophilized research vial.
• Combination: studying each substance separately does not establish the behavior of a fixed-ratio blend.

The FDA’s 2026 briefing materials also describe limited human information and unresolved characterization, immunogenicity, and safety questions for BPC-157- and TB-500-related bulk substances.^[17]

FDA identifies BPC-157 and the thymosin beta-4 fragment commonly called TB-500 among bulk substances that may present significant safety risks in compounding. The agency notes limited safety information, potential immunogenicity, aggregation, peptide-related impurities, and characterization concerns.^[6] These concerns are product- and route-sensitive and cannot be resolved by concentration math alone.

Human full-length thymosin beta-4 studies reported protocol-specific short-term tolerability, but they do not establish long-term safety for TB-500 fragments, repeated subcutaneous use, or coadministration with BPC-157.^[9][10] Likewise, the absence of serious events in a small BPC-157 pilot does not provide a comprehensive safety profile.^[5]

The World Anti-Doping Agency’s 2026 Prohibited List includes BPC-157 and lists thymosin beta-4 and its derivatives, including TB-500, under prohibited growth factors and growth-factor modulators.^[12] Athletes subject to anti-doping rules should not infer permissibility from a research label, online availability, or the absence of an approved medical indication.

Anti-doping status is separate from efficacy and safety. A prohibited-list entry does not validate a dosing protocol, and an educational calculation page does not provide a therapeutic-use exemption or sport-specific compliance advice.

The four reconstitution checks above remain the page’s strength-specific preparation framework. General subcutaneous references describe aseptic preparation, appropriate injection-site practices, and site rotation, but they do not validate this blend or its schedule.^[13][14]

• Record the compound name, 20 mg total vial strength, 3.0 mL final volume, approximately 6.67 mg/mL total concentration, and preparation date.
• Use a new sterile syringe for each preparation and administration and place used sharps directly into an appropriate sharps container.
• Follow the exact product label and lot documentation for storage, light protection, inspection, and discard instructions.
• Do not transfer a use-by period from another peptide, concentration, preservative system, or supplier record.

The linked Pure Lab Peptides page identifies the vial and supplier record used for this calculation.^[15]

What does a 20 mg BPC-157 + TB-500 blend contain?

This page uses a vial labeled as 10 mg BPC-157 plus 10 mg TB-500, for 20 mg total peptide material before reconstitution.

What concentration results from adding 3 mL?

The total blend concentration is approximately 6.67 mg/mL. If the labeled 1:1 ratio is accurate, each component is approximately 3.33 mg/mL.

How much peptide is one U-100 unit?

One U-100 unit is 0.01 mL. At 6.67 mg/mL, that volume contains approximately 66.7 mcg total blend, or about 33.3 mcg of each component.

Is TB-500 the same as thymosin beta-4?

They should not be treated as automatically interchangeable. Published human trials generally describe full-length synthetic or recombinant thymosin beta-4, while FDA materials identify TB-500 as a thymosin beta-4-related fragment.^[6][10]

Has the 10 mg + 10 mg blend been tested in a controlled human trial?

No controlled human trial cited on this page tested this fixed-ratio blend, reconstitution, and schedule. The displayed table is a transparent calculation framework, not a clinical recommendation.

Why is the 20 mg page different from the 10 mg page?

The two pages represent different vial strengths and concentrations. Their conversions, vial yields, and supply needs are strength-specific, while the underlying evidence limitations remain shared across the compound family.

Searches for Wolverine stack, BPC-157 and TB-500 stack, Wolverine stack dosage, or BPC-157 and TB-500 peptides commonly point to the same pairing. These are search and community labels, not names of an FDA-approved peptide therapy or a controlled combined recovery protocol.

• Soft tissue and injury terms: tendon and ligament research, soft tissue healing, tissue repair, tissue healing, injury healing, and injury recovery describe proposed research outcomes. The animal literature includes specific injury models, but it does not establish rapid healing, accelerated healing, or a dose for people.^[1][2][4]
• Local and systemic terms: an injection near an injury site, local injury site, local injury, and systemic recovery are not interchangeable exposure conditions. Published research does not establish that changing the injection site makes this fixed-ratio blend safe or effective.
• Blood-vessel terms: angiogenesis means new blood vessel formation. BPC-157 animal research and full-length thymosin beta-4 studies discuss vascular signaling and formation of new blood vessels, but those findings do not prove that TB-500 promotes recovery in this blend.^[3][7][8]
• Molecule terms: BPC-157 is a synthetic peptide sequence related to a protective protein fragment found in human gastric juice.^[1][16] TB-500 is described by FDA as a synthetic fragment of thymosin beta-4, not as a clinically interchangeable version of the naturally occurring protein.^[6][17]
• Regulatory terms: neither BPC-157 nor TB-500 is FDA-approved for human use. A research label, a supplier page, or online availability does not establish an approved indication, dosage range, or recovery protocol.^[6][17]

This distinction matters when comparing peptide protocols or using a peptide dosage calculator. The arithmetic can convert a labeled vial into volume markings, but it cannot determine potential benefits, select a clinical dose, or predict outcomes for someone recovering from injury.

How BPC-157 Works in Musculoskeletal Research

Claims that BPC-157 works by promoting tissue repair come largely from laboratory and animal studies. Proposed pathways include nitric-oxide signaling, fibroblast activity, collagen organization, and angiogenesis. Researchers have observed cells and vascular signals around experimental injury sites, but this does not establish a clinical dose or outcome in people.^{[2][3][4][16]}

What does BPC 157 mean?

BPC 157 is a common unhyphenated search variation for BPC-157. The name refers to a synthetic peptide sequence derived from a protective protein fragment found in human gastric juice. The naming variation does not identify a different compound.^[1][16]

What is known about BPC-157 alone versus the blend?

The BPC-157 evidence base primarily evaluates BPC-157 alone in preclinical injury models. Combining BPC-157 with a second substance introduces a different formulation and cannot be assumed to preserve the same exposure, interaction profile, or proposed effect.

Does the research establish oral BPC-157 or injection use for an acute injury?

No controlled human evidence cited here establishes oral BPC-157, a subcutaneous injection schedule, or a protocol tailored to acute injury, local injury, injury severity, or systemic recovery. Route and formulation differences prevent those uses from being inferred from animal research or a procedure-specific pilot.^[1][5]

Does TB-500 mobilize cells to injury sites?

Online descriptions sometimes state that TB-500 mobilizes cells to injury sites. Published mechanistic literature discusses cell migration for full-length thymosin beta-4, not a validated outcome from the injectable fragment in this 20 mg blend.^[7][8]

What does a TB-500 vial contain?

A TB-500 vial label identifies research material and mass, but a label alone does not establish sequence confirmation, purity, stability, clinical equivalence, or human dosing. FDA describes TB-500 as a synthetic fragment related to thymosin beta-4 and notes significant unresolved safety and characterization concerns.^[6][17]

TB-500 vs BPC-157: are they interchangeable?

No. They are different research substances discussed through different evidence bases. Neither a shared tissue-healing hypothesis nor marketing for peptides for recovery makes their biological effects, dosage ranges, or safety interchangeable.

Is TB-500 FDA approved?

No. Neither BPC-157 nor TB-500 is FDA-approved for human use, and this calculation page does not authorize peptide use or establish a therapeutic recovery protocol.^[6][17]

This page is an educational research reference and does not provide medical advice, diagnosis, treatment, or an individualized dose. The 20 mg blend schedule, per-component amounts, and U-100 markings above are retained as the site’s established calculation framework. They are not a substitute for a controlled study protocol, and the academic sources on this page should not be interpreted as validation of an injectable BPC-157 + TB-500 combination.

• 1
  HSS Journal (2025) - Systematic review of BPC-157 in orthopaedic sports medicine.

  View Source
• 2
  Journal of Orthopaedic Research (2003) - BPC-157 in a rat Achilles tendon transection model.

  View Source
• 3
  Journal of Physiology and Pharmacology (2010) - BPC-157, VEGF expression, and angiogenesis in muscle and tendon models.

  View Source
• 4
  Journal of Orthopaedic Research (2010) - BPC-157 in a rat medial collateral ligament injury model.

  View Source
• 5
  Alternative Therapies in Health and Medicine (2024) - Small BPC-157 pilot report in interstitial cystitis.

  View Source
• 6
  U.S. Food and Drug Administration - Potential safety risks associated with BPC-157 and the thymosin beta-4 fragment known as TB-500.

  View Source
• 7
  Annals of the New York Academy of Sciences (2007) - Thymosin beta-4 in development, repair, and regeneration.

  View Source
• 8
  Expert Opinion on Biological Therapy (2018) - Review of thymosin beta-4 mechanisms and clinical research.

  View Source
• 9
  Annals of the New York Academy of Sciences (2010) - Randomized single- and multiple-dose intravenous thymosin beta-4 study in healthy volunteers.

  View Source
• 10
  Clinical and Translational Science (2021) - Phase 1 recombinant human thymosin beta-4 study in healthy volunteers.

  View Source
• 11
  Annals of the New York Academy of Sciences (2010) - Phase 2 topical thymosin beta-4 study in venous ulcers.

  View Source
• 12
  World Anti-Doping Agency (2026) - Prohibited List naming BPC-157, thymosin beta-4, and TB-500.

  View Source
• 13
  Centers for Disease Control and Prevention - General principles for subcutaneous administration.

  View Source
• 14
  Pharmacologic Considerations of Subcutaneous Drug Administration - Review of subcutaneous-route variables and site considerations.

  View Source
• 15
  Pure Lab Peptides - BPC-157 + TB-500 20 mg research-vial supplier record.

  View Source
• 16
  Current Pharmaceutical Design (2018) - Review of BPC-157, angiogenic factors, and gastrointestinal healing research.

  View Source
• 17
  U.S. Food and Drug Administration (2026) - Pharmacy Compounding Advisory Committee briefing on BPC-157- and TB-500-related bulk substances.

  View Source

Explore the available research context, protocol variants or comparisons, and practical guides. When vial-size variants exist, they remain separate because vial strength, concentration, and syringe-unit calculations can differ. Related compounds and blends are comparisons only, not interchangeable.